Great Basin Scientific, Inc., a molecular diagnostic testing company, develops and commercializes molecular diagnostic systems that are designed to test hospital-acquired infections. The company's platform provides C. diff test, a rapid medical diagnostic test for the detection of C. diff, a gram-positive bacteria that causes severe diarrhea and other intestinal disorders. It also provides Group B streptococcus test, which is used to detect Group B streptococcus from an anal/vaginal swab of a pregnant woman. The company's assays in clinical trials include Staphylococcus identification and resistance blood infection panel that is designed to identify species of staphylococcus infections, detect the mecA gene that confers drug resistance directly from positive blood cultures, and provide information on the antibiotic resistance profile of the bacteria; and Shiga toxin producing Escherichia coli (E. coli) test that identifies shiga toxin produced by E. coli. Its assays under development include Staphyloccocus aureus (SA) pre-surgical nasal screen, a rapid test for the presence of SA in the nasal passages of a pre-surgical patient; Stool bacterial pathogenic panel, which is designed to detect the causes of food poisoning; Candida blood infections panel that is designed to identify the five species of Candida directly from positive blood cultures; Pertussis test for contagious respiratory disease caused by the bacterium Bordetella pertussis; and CT/NG test for chlamydia tracomatis/neisseria gonorrhoeae. The company sells its diagnostic tests through a direct sales force in the United States, as well as through distributors in the European Union and New Zealand. The company was formerly known as Diagnostic Micro Arrays, Inc. and changed its name to Great Basin Scientific, Inc. in April 2006. Great Basin Scientific, Inc. is headquartered in Salt Lake City, Utah.